Evaxion Biotech A/S Files 2024 Annual Report

Ticker: EVAX · Form: 20-F · Filed: 2025-04-01T00:00:00.000Z

Sentiment: neutral

Topics: annual-report, biotech, financials, personnel-changes

TL;DR

Evaxion Biotech's 2024 20-F is out, showing financials and exec changes. Check warrants and share prices.

AI Summary

Evaxion Biotech A/S filed its 20-F for the fiscal year ending December 31, 2024. The report details financial performance and business operations, including information on outstanding warrants and share prices. Key personnel changes noted include Mr. Norlén's resignation as CEO on September 1, 2023, and Mr. Vraniak's resignation as CFO.

Why It Matters

This filing provides investors with a comprehensive overview of Evaxion Biotech's financial health and strategic direction for the past fiscal year, impacting investment decisions.

Risk Assessment

Risk Level: medium — The company operates in the biotech sector, which is inherently high-risk due to research and development uncertainties and regulatory hurdles.

Key Numbers

20241231 — Fiscal Year End (The period covered by the 20-F filing.)
20250401 — Filing Date (The date the 20-F was submitted to the SEC.)
0001828253 — Central Index Key (Unique identifier for Evaxion Biotech A/S in SEC filings.)

Key Players & Entities

Evaxion Biotech A/S (company) — Filer of the 20-F report
Mr. Norlén (person) — Resigned as Chief Executive Officer effective September 1, 2023
Mr. Vraniak (person) — Resigned as Chief Financial Officer
USD 0.14 (dollar_amount) — Weighted average share price at exercise date for 2023
USD 2.42 (dollar_amount) — Weighted average share price at exercise date for 2022

FAQ

What was the weighted average share price at the date of exercise for warrants in 2023?

The weighted average share price at the date of exercise for warrants in 2023 was USD 0.14.

When did Mr. Norlén resign as CEO?

Mr. Norlén resigned as the Chief Executive Officer of the Company effective September 1, 2023.

What is the company's fiscal year end?

The company's fiscal year end is December 31.

What type of business is Evaxion Biotech A/S primarily involved in?

Evaxion Biotech A/S is primarily involved in Biological Products (No Diagnostic Substances).

What is the company's business address?

The company's business address is DR NEERGAARDS VEJ 5F, HOERSHOLM, G7, 2970.

From the Filing

0001171843-25-001916.txt : 20250401 0001171843-25-001916.hdr.sgml : 20250401 20250401093357 ACCESSION NUMBER: 0001171843-25-001916 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 176 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250401 DATE AS OF CHANGE: 20250401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25797112 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 20-F 1 evax20241231_20f.htm FORM 20-F evax20241231_20f.htm 0001828253 Evaxion Biotech A/S false --12-31 FY 2024 false false false false true false 1 0 5 10 0 1 0.1 2 27.52 4 4 7.53 2.24 2.42 1.28 1.50 1.02 0.14 2.08 1.41 0.40 1.72 1.19 6.5 6.5 4.46 3.66 2.96 1.83 1.83 1.83 2.42 2.23 2.23 1.94 1.02 0.75 0.75 2.96 1.83 1.83 1.83 2.42 2.23 2.23 1.94 1.02 1.50 0.75 2.96 1.83 1.83 1.83 2.42 2.23 2.23 0.1 20.0 7.0 6.0 7.0 6 7.0 6 10 3 5 5 0 0 The number of warrants presented includes warrants granted for share-based payments, the EIB Warrants, and 2023 SPA Investor Warrants outstanding as of each year end period. The weighted average share price at the date of exercise were, USD 0.14 and USD 2.42 for the years ended December 31, 2023, and 2022, respectively. Became a Board member in 2022. December 31, 2024, USD-end rate used. Board member until May 25, 2021. The number of warrants excludes 2023 SPA Investor Warrants and EIB Warrants referred to in Note 6. Mr. Norlén resigned as the Chief Executive Officer of the Company effective September 1, 2023. Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021. As of November 25, 2020, 26,964 warrants were granted for services provided before taking on the Board of Directors position. Mr. Karmark resigned as the Chief Financial Officer of the Company effective March 1, 2024. Became a member of Executive Management in 2023. Mr. Heegaard resigned from Chief Medical Officer of the company effective March 2024. 70,130,556 37,897,780 1 1 0001828253 2024-01-01 2024-12-31 xbrli:shares 0001828253 2024-12-31 0001828253 dei:BusinessContactMember 2024-01-01 2024-12-31 thunderdome:item iso4217:USD 0001828253 2023-01-01 2023-12-31 0001828253 2022-01-01 2022-12-31 iso4217:USD xbrli:shares 0001828253 2023-12-31 0001828253 ifrs-full:IssuedCapitalMember 2021-12-31 0001828253 ifrs-full:SharePremiumMember 2021-12-31 0001828253 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001828253 ifrs-full:RetainedEarningsMember 2021-12-31 0001828253 2021-12-31 0001828253 ifrs-full:IssuedCapitalMember 2022-01-01 2022-12-31 0001828253 ifrs-full:SharePremiumMember 2022-01-01 2022-12-31 0001828253 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-01-01 2022-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-12-31 0001828253 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001828253 ifrs-full:IssuedCapitalMember 2022-12-31 0001828253 ifrs-full:SharePremiumMember 2022-12-31 0001828253 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001828253 ifrs-full:RetainedEarningsMember 2022-12-31 0001828253 2022-12-31 0001828253 ifrs-full:IssuedCapitalMember 2023-01-01 2023-12-31 0001828253 ifrs-full:SharePremiumMember 2023-01-01 2023-12-31 0001828253 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-01-01 2023-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-12-31 0001828253 ifrs-full:RetainedEa